Cardiac Biomarkers, Intensive Lifestyle Intervention, and Heart Failure Subtypes in Diabetes: Look AHEAD Cardiac Biomarker Ancillary Study.


Por: Chunawala Z, Patel KV, Garcia KR, Segar MW, Verma S, Bayes-Genis A, Pop-Busui R, Bhatt DL, Januzzi JL Jr, Butler J, Lam CSP, Bertoni AG, Espeland M and Pandey A

Publicada: 1 mar 2026 Ahead of Print: 7 nov 2025
Resumen:
BACKGROUND: N-terminal pro-B-type natriuretic peptide (NT-proBNP) identifies elevated risk for developing heart failure (HF) in type 2 diabetes (T2D). Whether risk of HF subtypes associated with NT-proBNP is modifiable with an intensive lifestyle intervention (ILI) targeting weight loss is unknown. OBJECTIVES: This study aims to evaluate the association of baseline and longitudinal changes in NT-proBNP with risk of HF subtypes in T2D. In addition, we assessed whether NT-proBNP modified the association of an ILI with risk of HF subtypes. METHODS: Adults with T2D and overweight or obesity in the Look AHEAD trial were included (n = 3,959). Associations of baseline and 1-year changes in NT-proBNP with risk of HF subtypes (left ventricular ejection fraction =50% [heart failure with preserved ejection fraction (HFpEF)] and <50% (heart failure with reduced ejection fraction (HFrEF)] were evaluated in adjusted Cox models. Multiplicative interaction testing was performed to evaluate heterogeneous treatment effects of the ILI on HF subtypes across NT-proBNP concentrations. RESULTS: Elevated NT-proBNP (=125 pg/mL) at baseline and increasing NT-proBNP over 1-year follow-up (vs stable or decreasing) were each significantly associated with higher risk of both HF subtypes. The ILI was associated with lower HFpEF risk among participants with elevated but not nonelevated baseline NT-proBNP (HRs for ILI vs diabetes support and education (DSE): HR: 0.47 (95% CI: 0.24-0.90) and HR: 1.65 (95% CI: 0.93-2.91), respectively; P for interaction = 0.003). Participants with stable or decreasing, but not increasing, NT-proBNP at 1-year follow-up had lower HFpEF risk with the ILI (HRs for ILI vs DSE: HR: 0.58 (95% CI: 0.34-0.99) and HR: 1.48 (95% CI: 0.61-3.56), respectively; P for interaction = 0.01). The ILI was not significantly associated with HFrEF risk across baseline or 1-year change in NT-proBNP categories. CONCLUSIONS: In T2D, NT-proBNP can inform HF risk assessment and identify individuals who are more likely to benefit from an ILI. (Look AHEAD: Action for Health in Diabetes [Look AHEAD]; NCT00017953).

Filiaciones:
Chunawala Z:
 Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA

Patel KV:
 Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA

Garcia KR:
 Department of Biostatistics and Data Sciences, Wake Forest University School of Medicine, Wake Forest University, Winston-Salem, North Carolina, USA

Segar MW:
 Department of Cardiology, Texas Heart Institute, Houston, Texas, USA

Verma S:
 Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada

:
 Heart Institute, Hospital Germans Trias i Pujol, CIBERCV, Badalona, Spain

Pop-Busui R:
 Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA

 Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon, USA

Bhatt DL:
 Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Januzzi JL Jr:
 Baim Institute for Clinical Research, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

Butler J:
 Baylor Scott and White Research Institute, Dallas, Texas, USA

 Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA

Lam CSP:
 National Heart Centre Singapore, Duke-National University of Singapore, Singapore

Bertoni AG:
 Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA

Espeland M:
 Department of Biostatistics and Data Sciences, Wake Forest University School of Medicine, Wake Forest University, Winston-Salem, North Carolina, USA

 Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA

Pandey A:
 Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
ISSN: 22131779





JACC-HEART FAILURE
Editorial
Elsevier BV, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND, Países Bajos
Tipo de documento: Article
Volumen: 14 Número: 3
Páginas: 102726-102726
WOS Id: 001708577100001
ID de PubMed: 41204924

MÉTRICAS